Avipep is using proprietary antibody fragments, AvibodiesTM, to deliver payloads to tumour cells more efficiently than intact antibodies. Avibodies represent a flexible platform for imaging, Antibody-Drug Conjugates (ADC’), RadioImmunotherapy (RIT) and delivery of Immunomodulators.
The concept of using antibodies to deliver payloads to targets has been in development for over three decades. Like many medical innovations, technical issues have taken considerable time to resolve and now, with recent approvals of two Antibody Drug Conjugates (ADC), Kadcyla and Adcetris, the field is advancing rapidly.
Avipep’s platform offer significant improvements over other approaches. The completion of a clinical study of Avipep’s AVP04 using PET imaging in 2015 demonstrated a superior level of payload delivery to tumours. This should translate into higher clinical efficacy with lower systemic toxicity, i.e. a greater therapeutic window.